View All Documents & Correspondence
Human Serum Albumin Containing Culture Medium For Growth Of Neural Stem Cells
Abstract: Provided are for example: a human serum albumin containing culture medium for the growth of neural stem cells and/or neural progenitor cells that promotes cell growth while maintaining the undifferentiation potency and multipotency of neural stem cells and/or neural progenitor cells; and a method for growing neural stem cells and/or neural progenitor cells by using said culture medium.
Notices, Deadlines & Correspondence
Patent Information
Applicants
AJINOMOTO CO., INC.
Inventors
1. MATSUMOTO, Takuya
2. SENDA, Sho
3. KOBAYASHI, Tsuyoshi
Specification
Claims
1. A medium for neural stem cells and/or neural progenitor cells, comprising human serum albumin.
2. The medium according to claim 1, which is for maintaining undifferentiation of neural stem cells and/or neural progenitor cells.
3. The medium according to claim 1 or 2, which is for promoting proliferation of neural stem cells and/or neural progenitor -cells.
4. The medium according to any one of claims 1 to 3, which is for maintaining undifferentiation of and promoting proliferation of neural stem cells and/or neural progenitor cells.
5. The method according to any one of claims 1 to 4, wherein the neural stem cells and/or neural progenitor cells are derived from pluripotent stem cells.
6. The medium according to any one of claims 1 to 5, wherein the human serum albumin is a recombinant human serum albumin.
7. The medium according to any one of claims 1 to 5, wherein the human serum albumin is derived from human plasma.
8. The medium according to any one of claims 1 to 7, which comprises fatty acid in the medium.
9. The medium according to any one of claims 1 to 8, wherein the amount of the fatty acid in the medium is not more than 50 uM.
10. The medium according to any one of claims 1 to 9, wherein the amount of the fatty acid in the medium is not more than 20 uM.
11. The medium according to any one of claims 1 to 10, wherein the amount of the human serum albumin in the medium is not less than 0.2 mg/mL. and not more than 20 mg/mL.
12. The medium according to any one of claims 1 to 11, wherein the amount of the human serum albumin in the medium is not less than 0.5 mg/mL and not more than 10 mg/mL.
13. The medium according to any one of claims 1 to 12, which is for suspension culture.
14. The medium according to any one of claims 1 to 13, which is a serum-free medium.
15. The medium according to any one of claims 1 to 14, which comprises basic fibroblast growth factor (bFGF).
16. The medium according to claim 15, wherein the amount of the bFGF in the medium is not less than 1 ng/mL and not more than 200 ng/mL.
17. A method of proliferating neural stem cells and/or neural progenitor cells, comprising adding human serum albumin to a medium.
18. A method of maintaining undifferentiation of neural stem cells and/or neural progenitor cells, comprising adding liuman serum albumin to a medium.
19. A method of promoting proliferation of neural stem cells and/or neural progenitor cells while maintaining
undifferentiation thereof, comprising adding human serum albumin to a medium.
20. The method according to any one of claims 17 to 19, wherein the neural stem cells and/or neural progenitor cells are derived from pluripotent stem cells.
21. The method according to any one of claims 17 to 20, wherein the human serum albumin is recombinant human serum albumin.
22. The method according to any one of claims 17 to 20, wherein the human serum albumin is derived from human plasma.
23. The method according to any one of claims 17 to 22, wherein the medium comprises fatty acid.
24. The method according to any one of claims 17 to. 23, wherein the amount of the fatty acid in the medium is not more than 50 uM.
25. The method according to any one of claims 17 to 24, wherein the amount of the fatty acid in the medium is not more than 2 0 uM.
26. The method according to any one of claims 17 to 25, wherein the amount of the human serum albumin in the medium is not less than 0.2 mg/mL and not more than 20 mg/mL.
27. The method according to any one of claims 17 to 26, wherein the amount of the human serum albumin in the medium is not less than 0.5 mg/mL and not more than 10 mg/mL.
28. The method according to any one of claims 17 to 27, wherein the neural stem cells and/or neural progenitor cells are cultured in suspension in the medium.
29. A culture composition comprising the medium according to any of claims 1 to 16 and neural stem cells and/or neural progenitor cells.
Documents
Application Documents
| # | Name | Date |
|---|---|---|
| 1 | 201747037312-TRANSLATIOIN OF PRIOIRTY DOCUMENTS ETC. [23-10-2017(online)].pdf | 2017-10-23 |
| 2 | 201747037312-STATEMENT OF UNDERTAKING (FORM 3) [23-10-2017(online)].pdf | 2017-10-23 |
| 3 | 201747037312-PROOF OF RIGHT [23-10-2017(online)].pdf | 2017-10-23 |
| 4 | 201747037312-PRIORITY DOCUMENTS [23-10-2017(online)].pdf | 2017-10-23 |
| 5 | 201747037312-POWER OF AUTHORITY [23-10-2017(online)].pdf | 2017-10-23 |
| 6 | 201747037312-FORM 1 [23-10-2017(online)].pdf | 2017-10-23 |
| 7 | 201747037312-DRAWINGS [23-10-2017(online)].pdf | 2017-10-23 |
| 8 | 201747037312-DECLARATION OF INVENTORSHIP (FORM 5) [23-10-2017(online)].pdf | 2017-10-23 |
| 9 | 201747037312-COMPLETE SPECIFICATION [23-10-2017(online)].pdf | 2017-10-23 |
| 10 | 201747037312-CLAIMS UNDER RULE 1 (PROVISIO) OF RULE 20 [23-10-2017(online)].pdf | 2017-10-23 |
| 11 | Correspondence by Agent_Form-1_24-10-2017.pdf | 2017-10-24 |
| 12 | 201747037312.pdf | 2017-10-25 |
| 13 | 201747037312-FORM 3 [12-04-2018(online)].pdf | 2018-04-12 |
| 14 | 201747037312-FORM 18 [19-03-2019(online)].pdf | 2019-03-19 |
| 15 | 201747037312-FER.pdf | 2021-10-17 |
Search Strategy
| 1 | 2020-12-0812-08-19(1)E_08-01-2021.pdf |